The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
An article from
Dive Brief
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
Published Aug. 13, 2026
Taiho Oncology and Cullinan Therapeutics are developing a targeted lung cancer drug.
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Taiho and Cullinan's zipalertinib hits its Phase 3 goal in lung cancer, setting up a fight with J&J's Rybrevant.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3…
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy. |…
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
